Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups

“The take-home message is that there’s not a population, at least at this point, that we can tease out and [deem] the population that needs olaparib right now. It seems that benefit with [the addition of olaparib maintenance to durvalumab and chemotherapy] was observed across all the subgroups. I do think there’s a population that benefits more…[but] it has yet to be determined."

Shannon Westin, MD, MPH, FACOG, the director of Early Drug Development and the Phase I Trials Department, and a professor in the Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, at The University of Texas MD Anderson Cancer Center, discusses findings from a post-hoc exploratory analysis of phase 3 DUO-E trial (NCT04269200) evaluating biomarker and histological heterogeneity, the presence of baseline ctDNA, and efficacy in patients with pMMR recurrent endometrial cancer receiving durvalumab (Imfinzi) with or without olaparib (Lynparza) plus chemotherapy.